Business context

The pitch.

01

Metabolic health market evolution

The k-shaped market is diverging quickly as technology shifts re-imagine what is possible and who can access it.

The K-shaped digital health market
User experience and company valuation
2018 2020 2022 2024 2026 GLP-1 MAINSTREAM ADOPTION (~2023) D2C · RACE TO TOP ↑ B2B2C · RACE TO BOTTOM ↓
D2C · Race to the top

Consumer-paid solutions compete on personalization, convenience, and experience. Advances in hardware and AI are pushing the market forward faster than ever, which is driving the solutions to cater to the "healthy wealthy".

AI-native personalization for members and care teams
Access to increasingly precise health measurements
Captures high-willingness-to-pay health optimizers
B2B2C · Race to the bottom

Employer and health plan oriented solutions optimize for ROI and coverage, suppressing innovation. Because of this, products are slow to adopt consumer demanded features.

Program design and evidence developed in pre-AI era
Optimized for population health with templatized care plans
Consumer experiences feel like "insurance products" rather than "benefits"
GLP-1s are widening the K
GLP-1s are a key trend in metabolic health and their affordability gap is accelerating the market split.
D2C platforms give access to GLP-1s in a cheaper and frictionless way and do not have constraints from health plans.
Due to cost concerns, employers are not covering the medications or restricting access through utilization management solutions.
GLP-1s bypass lifestyle change for quick results, forcing a choice between a lifetime prescription or a weight rebound
Metabolic health is getting worse, especially for men
88%
of Americans
lack optimal metabolic health, a figure that has worsened over the last decade despite growing digital health spend.
Araújo et al., Metabolic Syndrome and Related Disorders, 2019. NHANES 2009–2016.
Higher
visceral fat burden in men
Men carry significantly more visceral adipose tissue than women at every BMI level, the fat type most directly linked to metabolic disease and early mortality.
Karastergiou et al., BMC Medicine, 2012; Neeland et al., Circulation, 2019.
10 pts
lower telehealth engagement
42% of women vs. 32% of men used telehealth in the past year. Men, the population carrying greater metabolic risk, are the least engaged with digital care.
Rock Health Consumer Adoption Survey, 2021.
02

AI innovation

When deployed in a truly consumer-centric way, AI has the ability to establish true personalization, create consumer delight, and make the delivery of services better for all constituents.

AI-ENABLED ZONE BOUTIQUE CARE B2B2C D2C + AI SCALE → PERSONALIZATION ↑
01
Personalization at scale wasn't possible before AI

The B2B2C ROI model required standardized, population-level interventions. True 1:1 personalization was only available in boutique, high-cost care that couldn't scale.

2020 2021 2022 2023 2024 CONSUMER-FACING AI GROWTH
02
AI is becoming ubiquitous

Generic AI-driven chatbot experiences have eroded consumer trust. Today's members expect AI that feels invisible and helpful, not a wellness FAQ bot.

BETTER CONSUMER EXPERIENCE REDUCED FRICTION FOR MEMBERS LOWER COGNITIVE LOAD FOR CARE TEAMS D2C ONLY TODAY
03
AI in healthcare needs to sit below the surface for members

The best AI in healthcare is invisible. It reduces friction for members and cognitive load for care teams, freeing coaches to focus on relationships rather than administration. D2C models are working to optimize for this.

03

Market opportunity

The B2B2C metabolic health market is large and growing, but legacy programs were designed before DEXA scans and AI personalization capabilities existed. Bringing these tools in unlocks a step-change in ROI that employers have never been able to demonstrate before.

Total addressable market
$25B
The U.S. corporate wellness market, where technology-driven and data-informed metabolic programs are not yet the standard of care. Legacy vendors have never integrated precision measurement or AI personalization.
Growing to $44B by 2035 · 6.6% CAGR
Precedence Research, Corporate Wellness Market, 2026.
Serviceable obtainable market
$1B
Metabolic health within the B2B2C channel, approached with precision measurement and AI personalization that no legacy vendor currently offers.
3–5 year realistic capture horizon
At Last Health analysis, derived from TAM segmentation.
04

Value propositions

At Last Health delivers value that drives to each constituent's bottom line.

Members
A consumer-grade health benefit, at no cost

Free access to a metabolic health service built to the standard of the best D2C products on the market. Human coaches, cutting-edge tracking technologies, and personalized AI-driven guidance, all delivered as an employer benefit.

Employers
A broadly applicable benefit with trackable ROI

Offer a benefit relevant to the majority of your population while driving medical cost savings that are easily measurable. Metabolic health improvement translates directly to reduced claims, fewer chronic disease complications, and lower overall healthcare spend.

Payers
Lower total cost of care across populations

By improving the metabolic health profile of members at the population level, At Last Health reduces downstream utilization: fewer hospitalizations, fewer chronic disease progressions, and a meaningfully lower total cost of care over time.

Brokers
A plan-agnostic solution with guaranteed ROI

A population health solution that deploys across health plan types and guarantees medical cost savings ROI, making it easy to recommend to employer clients regardless of their existing benefits architecture.

Health Systems
Manage to outcomes in risk-based contracts

For health systems operating under value-based and risk-based contracts, improving the metabolic health of their patient population directly improves their ability to hit outcome targets. At Last Health gives health systems a scalable, evidence-based program to deploy between visits, reducing downstream utilization and supporting performance against quality metrics.

Providers
A trusted referral for patients between visits

For patients who struggle to take consistent healthy actions between appointments, referrals to At Last Health give providers a credible, evidence-based program they can confidently recommend to drive meaningful metabolic improvement.

05

Next steps

Anchoring in research will create momentum to quickly scale the business post-trial.

01 — Build
Build V1 of the product

Develop the first version of the product in collaboration with a behavioral scientist and a researcher, ensuring the experience is grounded in evidence from day one.

02 — Launch
Sign an enterprise client as a trial partner

Identify and onboard a commercial enterprise client willing to participate as a trial candidate, providing real-world access to members and critical data needed to validate our approach.

03 — Publish
Conduct a research study and publish results to push the market forward

Run a 6-12 month study on members to evaluate program efficacy, then publish the findings, establishing At Last Health's evidence base and credibility in the clinical and employer markets.